The Novartis Institute for Tropical Diseases, a joint venture of the Swiss pharmaceutical giant and the Singapore Economic Development board, has the goal of getting at least two vaccines into the clinic by 2008, and onto the market by 2013, Novartis said. The center will be funded with $162.2 million over the next eight years, according to Novartis.
The institute first began operations last year. Over 70 scientists and 30 students are slated to be working at the institute by the end of 2004.
The drug discovery activities at the Novartis institute will involve development of screening assays and target discovery. Biopolis also houses a DNA sequencing facility.